trending Market Intelligence /marketintelligence/en/news-insights/trending/bxdJXzy4A2Iecv1WRTyZhQ2 content esgSubNav
In This List

Emergent buys Sanofi's smallpox vaccine biz

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Emergent buys Sanofi's smallpox vaccine biz

Emergent BioSolutions Inc. completed the acquisition of Sanofi SA's smallpox vaccine ACAM2000, including two manufacturing facilities: one in Canton, Mass., and another in Rockville, Md.

The Maryland-based company paid $117.5 million in upfront cash and will pay a further $7.5 million once certain conditions are met.

Emergent will also assume responsibility for an existing 10-year contract valued at up to $425 million with the Centers for Disease Control and Prevention.

The contract has a remaining value of about $160 million for deliveries of ACAM2000 to the Strategic National Stockpile.